The successful American and German vaccine against COVID 19 is planned to produce 50 million this year (2020)

 

The successful American and German vaccine against COVID 19 is planned to produce 50 million this year

Pfizer in the United States and BioNTech in Germany, which have been shown to be 90% successful against the virus, plan to produce 50 million vaccines this year.

The company announced the success of the third clinical trial on November 8. This vaccine is named BNT162b2.

This mRNA based BNTI62b2 vaccine has shown very good results against the SARS-CoV-2 virus. The vaccine was given to people who had not previously been infected with the virus, and the first interim effectiveness analysis conducted on November 8 showed its success. The vaccine has been clinically third-degree. According to Pfizer, the vaccine is expected to reach 50 million doses by 2020 and 1.3 billion by 2021.

With this, it has been suggested that the two companies will earn $ 13 billion in the future from the production of the vaccine. The European Union has already ordered 200 million of those vaccines, while the United Kingdom has ordered 40 million. Pfizer has already agreed to supply 100 million vaccines to the United States at a single dose of US $ 19.50. According to the company, two doses of the vaccine are needed to protect against the virus. Accordingly, the cost per patient is $ 39.